Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
ABBV Logo

Abbvie Inc.

ABBV

Pharmaceutical Preparations

Mkt Cap

$286.5B

PE

59.44

Debt

$66.44B

Cash

$12.81B

EV

$340.1B

FCF

$22.06B

Market Cap

$286.5B

P/E Ratio

59.44

Debt

$66.44B

Cash

$12.81B

EV

$340.1B

FCF

$22.06B
Charts data: {"Earnings":[{"time":"2014-12-30","value":1774000000},{"time":"2015-12-30","value":5144000000},{"time":"2016-12-30","value":5923000000},{"time":"2017-12-30","value":5283000000},{"time":"2018-12-30","value":5657000000},{"time":"2019-12-30","value":7842000000},{"time":"2020-12-30","value":4556000000},{"time":"2021-12-30","value":11468000000},{"time":"2022-12-30","value":11782000000},{"time":"2023-12-30","value":4820000000}],"Sales":[{"time":"2014-12-30","value":19960000000},{"time":"2015-12-30","value":22859000000},{"time":"2016-12-30","value":25638000000},{"time":"2017-12-30","value":28216000000},{"time":"2018-12-30","value":32753000000},{"time":"2019-12-30","value":33266000000},{"time":"2020-12-30","value":45804000000},{"time":"2021-12-30","value":56197000000},{"time":"2022-12-30","value":58054000000},{"time":"2023-12-30","value":54318000000}],"Net Margins":[{"time":"2014-12-30","value":0.08887775551102205},{"time":"2015-12-30","value":0.22503171617306095},{"time":"2016-12-30","value":0.2310242608627818},{"time":"2017-12-30","value":0.1872341933654664},{"time":"2018-12-30","value":0.17271700302262388},{"time":"2019-12-30","value":0.23573618709793784},{"time":"2020-12-30","value":0.0994672954327133},{"time":"2021-12-30","value":0.20406783280246277},{"time":"2022-12-30","value":0.20294897853722396},{"time":"2023-12-30","value":0.0887366987002467}],"Assets":[{"time":"2014-12-30","value":27547000000},{"time":"2015-12-30","value":53050000000},{"time":"2016-12-30","value":66099000000},{"time":"2017-12-30","value":70786000000},{"time":"2018-12-30","value":59352000000},{"time":"2019-12-30","value":89115000000},{"time":"2020-12-30","value":150565000000},{"time":"2021-12-30","value":146529000000},{"time":"2022-12-30","value":138805000000},{"time":"2023-12-30","value":134711000000}],"Stockholders Equity":[{"time":"2014-12-30","value":1742000000},{"time":"2015-12-30","value":3945000000},{"time":"2016-12-30","value":4636000000},{"time":"2017-12-30","value":5097000000},{"time":"2018-12-30","value":-8446000000},{"time":"2019-12-30","value":-8172000000},{"time":"2020-12-30","value":13097000000},{"time":"2021-12-30","value":15436000000},{"time":"2022-12-30","value":17287000000},{"time":"2023-12-30","value":10397000000}],"ROE":[{"time":"2014-12-30","value":1.0183696900114811},{"time":"2015-12-30","value":1.3039290240811154},{"time":"2016-12-30","value":1.2776100086281277},{"time":"2017-12-30","value":1.0364920541494997},{"time":"2018-12-30","value":-0.6697845133791144},{"time":"2019-12-30","value":-0.959618208516887},{"time":"2020-12-30","value":0.3478659234939299},{"time":"2021-12-30","value":0.7429385851256802},{"time":"2022-12-30","value":0.6815526117892058},{"time":"2023-12-30","value":0.4635952678657305}],"ROA":[{"time":"2014-12-30","value":0.12382473590590627},{"time":"2015-12-30","value":0.14207351555136663},{"time":"2016-12-30","value":0.14196886488449145},{"time":"2017-12-30","value":0.13550702116237673},{"time":"2018-12-30","value":0.11027429572718696},{"time":"2019-12-30","value":0.14568815575380126},{"time":"2020-12-30","value":0.0754690665161226},{"time":"2021-12-30","value":0.12232390857782419},{"time":"2022-12-30","value":0.1305212348258348},{"time":"2023-12-30","value":0.09469902235155259}]}

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Sector

  • ABCL Logo

    ABCL

  • ABT Logo

    ABT

  • ABUS Logo

    ABUS

  • AGIO Logo

    AGIO

  • AKRO Logo

    AKRO

  • ALKS Logo

    ALKS

  • ALNY Logo

    ALNY

  • ALPN Logo

    ALPN

  • AMPH Logo

    AMPH

  • AMRN Logo

    AMRN

  • AMRX Logo

    AMRX

  • ANAB Logo

    ANAB

  • ANIP Logo

    ANIP

  • APLS Logo

    APLS

  • ARCT Logo

    ARCT

  • ARDX Logo

    ARDX

  • ARQT Logo

    ARQT

  • ARVN Logo

    ARVN

  • ARWR Logo

    ARWR

  • ATAI Logo

    ATAI

  • AUPH Logo

    AUPH

  • AVDL Logo

    AVDL

  • AVIR Logo

    AVIR

  • AVTE Logo

    AVTE

  • AXSM Logo

    AXSM

  • BBIO Logo

    BBIO

  • BCYC Logo

    BCYC

  • BGNE Logo

    BGNE

  • BHVN Logo

    BHVN

  • BMEA Logo

    BMEA

  • BMRN Logo

    BMRN

  • BMY Logo

    BMY

  • BPMC Logo

    BPMC

  • CBAY Logo

    CBAY

  • CDMO Logo

    CDMO

  • CERE Logo

    CERE

  • CMPS Logo

    CMPS

  • CNTA Logo

    CNTA

  • COGT Logo

    COGT

  • COLL Logo

    COLL

  • CORT Logo

    CORT

  • CPRX Logo

    CPRX

  • CRNX Logo

    CRNX

  • CTLT Logo

    CTLT

  • CYRX Logo

    CYRX

  • CYTK Logo

    CYTK

  • DAWN Logo

    DAWN

  • DCPH Logo

    DCPH

  • DVAX Logo

    DVAX

  • DYN Logo

    DYN

  • ELAN Logo

    ELAN

  • ENTA Logo

    ENTA

  • EOLS Logo

    EOLS

  • ERAS Logo

    ERAS

  • ETNB Logo

    ETNB

  • EWTX Logo

    EWTX

  • FHTX Logo

    FHTX

  • FOLD Logo

    FOLD

  • FULC Logo

    FULC

  • GERN Logo

    GERN

  • GPCR Logo

    GPCR

  • HRMY Logo

    HRMY

  • HROW Logo

    HROW

  • HZNP Logo

    HZNP

  • IDYA Logo

    IDYA

  • IGMS Logo

    IGMS

  • INSM Logo

    INSM

  • INVA Logo

    INVA

  • IONS Logo

    IONS

  • IRON Logo

    IRON

  • IRWD Logo

    IRWD

  • ITCI Logo

    ITCI

  • JANX Logo

    JANX

  • JAZZ Logo

    JAZZ

  • JNJ Logo

    JNJ

  • KALV Logo

    KALV

  • KNSA Logo

    KNSA

  • KROS Logo

    KROS

  • KRTX Logo

    KRTX

  • KURA Logo

    KURA

  • LGND Logo

    LGND

  • LLY Logo

    LLY

  • LQDA Logo

    LQDA

  • LXRX Logo

    LXRX

  • LYEL Logo

    LYEL

  • MDGL Logo

    MDGL

  • MGNX Logo

    MGNX

  • MIRM Logo

    MIRM

  • MLTX Logo

    MLTX

  • MNKD Logo

    MNKD

  • MORF Logo

    MORF

  • MRK Logo

    MRK

  • MRNS Logo

    MRNS

  • MRUS Logo

    MRUS

  • MRVI Logo

    MRVI

  • NATR Logo

    NATR

  • NRIX Logo

    NRIX

  • OCUL Logo

    OCUL

  • OGN Logo

    OGN

  • OLMA Logo

    OLMA

  • OPK Logo

    OPK

  • ORGO Logo

    ORGO

  • ORIC Logo

    ORIC

  • PAHC Logo

    PAHC

  • PBAJ Logo

    PBAJ

  • PBH Logo

    PBH

  • PCRX Logo

    PCRX

  • PFE Logo

    PFE

  • PGEN Logo

    PGEN

  • PHAT Logo

    PHAT

  • PLRX Logo

    PLRX

  • PRGO Logo

    PRGO

  • PRTA Logo

    PRTA

  • PTCT Logo

    PTCT

  • PTGX Logo

    PTGX

Growth

%

%

Discount

%

%

Multiple

g\r+10%+11%+12%+13%+14%
0%109887
+1%1110988
+2%13111098
+3%141311109
+4%1714121110
Years012345678910TV
FCF$22.06B$26.87B$32.22B$38.04B$44.2B$50.53B$56.83B$62.85B$68.34B$73.03B$76.68B$766.8B
DCF$23.36B$24.36B$25.01B$25.27B$25.12B$24.57B$23.63B$22.34B$20.76B$18.95B$189.5B
Value$422.9B

In the chart Earnings are multiplied by this value.

Earnings Growth 9.4%
Earnings Stability 33%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-201512-201612-201712-201812-201912-202012-202112-202212-2023TTM
Net Margin23%23%19%17%24%9.9%20%20%8.9%8.9%
ROA14%14%14%11%15%7.5%12%13%9.5%9.5%
ROE130%130%100%-67%-96%35%74%68%46%46%

What is the average Net Margin?

The average Net Margin over the past 5 years is +16.73%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -1.18%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is +11.32%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -0.22%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is +10.11%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +31.39%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-201512-201612-201712-201812-201912-202012-202112-202212-2023TTM
Debt FCF4.465.613.923.035.565.564.022.773.013.01
Debt Equity7.937.947.25-4.58-8.697.135.733.896.396.39
MIN
Graham Stability--100%100%100%73%100%100%52%52%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is 3.01.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -0.28.

What is the Graham’s Stability?

Graham’s Stability measure stands at 0.52.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-201612-201812-202012-2022Trend
Revenue11%11%5.8%-6.4%-1.1%
Net Income-2.9%-3.2%1.9%-59%-13%
Stockholders Equity12%--7.4%-40%-11%
FCF19%12%9.5%-9%-9.5%

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +10.65%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -1.06%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -3.15%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -12.62%.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -11.48%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +11.52%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -9.5%.